Discover
what's new
FILTER BY:
ORDER BY:
THE SYDNEY MEMORY AND AGEING STUDY
THE SYDNEY MEMORY AND AGEING STUDY
Prof Henry Brodaty discusses mild cognitive impairment and key findings from one of Australia’s largest and longest running studies of ageing and cognitive health.
Login Required
DELINEATING THE CAUSE OF MEMORY IMPAIRMENT
DELINEATING THE CAUSE OF MEMORY IMPAIRMENT
An expert panel discusses a patient case study which highlights the Alzheimer’s continuum as well as the challenges of detecting early cognitive change at the 6th Congress of the European Academy of Neurology (EAN) 2020.
Login Required
WHAT DOES AN EARLY DIAGNOSIS MEAN FOR PATIENTS?
WHAT DOES AN EARLY DIAGNOSIS MEAN FOR PATIENTS?
Delays in diagnosis of Alzheimer’s disease can mean lost opportunities for medical and social intervention. Prof Henry Brodaty discusses the importance of a timely diagnosis, what barriers remain and what the future holds for people living with dementia.
Login Required
THE MULTIDISCIPLINARY MEMORY CLINIC
THE MULTIDISCIPLINARY MEMORY CLINIC
A/Prof Rebekah Ahmed shares her insights into how an integrated multidisciplinary approach can enhance and streamline Alzheimer’s disease diagnosis and management in memory clinics.
Login Required
HOW DO WE BETTER DETECT AND REFER PATIENTS EARLIER?
HOW DO WE BETTER DETECT AND REFER PATIENTS EARLIER?
Dr Kathleen Welsh-Bohmer discusses future innovations and the use of digital detection tools and telemedicine to improve early diagnosis at the Alzheimer’s Association International Conference (AAIC) 2020.
Login Required
EXPLORING PATHOLOGICAL OBSTACLES
EXPLORING PATHOLOGICAL OBSTACLES
An expert panel discusses the diagnostic challenges of mixed pathology in patients with Alzheimer’s disease through a patient case study at the International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD) 2019.
Login Required
LEVERAGING BIOMARKERS FOR AN EARLIER DIAGNOSIS
LEVERAGING BIOMARKERS FOR AN EARLIER DIAGNOSIS
From neuroimaging to CSF and blood-based biomarkers, Prof Chris Rowe discusses the future use of biomarkers for aiding the early diagnosis of Alzheimer’s disease at the Alzheimer’s Association International Conference (AAIC) 2020.
Login Required
MCI ON THE ALZHEIMER’S CONTINUUM
MCI ON THE ALZHEIMER’S CONTINUUM
Our understanding of MCI is changing as clinical research pushes the threshold for diagnosis earlier in the disease continuum. Prof Philip Morris AM and A/Prof Michael Woodward discuss current clinical challenges on the MindChangers podcast.
Login Required
THE AMYLOID PUZZLE
THE AMYLOID PUZZLE
Prof Colin Masters and A/Prof David Darby share their insights into the current concepts and controversies in the neurobiology of Alzheimer’s disease on the MindChangers podcast.
Login Required
MARKING THE WAY TOWARDS EARLY DIAGNOSIS
MARKING THE WAY TOWARDS EARLY DIAGNOSIS
Biomarkers have the potential to push the limits of early detection into uncharted territory. On this MindChangers podcast episode, Prof Chris Rowe and Dr Qiao-Xin Li discuss how PET imaging and CSF biomarker testing are about to change the diagnosis of Alzheimer’s disease.
Login Required
IS A SIMPLE TEST A STEP CLOSER?
IS A SIMPLE TEST A STEP CLOSER?
Innovative new technologies have the potential to make biomarker testing for Alzheimer’s disease quicker, easier and less invasive for patients. A/Prof Peter van Wijngaarden and Prof Ashley Bush discuss what is on the horizon in this episode of the MindChangers podcast.
Login Required
THE FUTURE OF ALZHEIMER’S STARTS HERE
THE FUTURE OF ALZHEIMER’S STARTS HERE
Dementia Australia CEO Maree McCabe and Lucy O’Flaherty from Korongee Dementia Village discuss how Australia is preparing for the future in this episode of the MindChangers podcast series.
Login Required
THE STAGES OF ALZHEIMER’S DISEASE
THE STAGES OF ALZHEIMER’S DISEASE
An overview of international definitions for MCI and the Alzheimer’s continuum. How has our definition changed due to advances in biomarkers and a deeper understanding of pathological changes?
Login Required
ACHIEVING A QUICKER ROUTE TO DIAGNOSIS
ACHIEVING A QUICKER ROUTE TO DIAGNOSIS
The mean time from symptom onset to receiving a diagnosis is approximately 3 years.4 What are the current challenges and trends when it comes to early diagnosis of Alzheimer’s disease in Australia?
Login Required
GUIDELINES FOR THE USE OF BIOMARKERS
GUIDELINES FOR THE USE OF BIOMARKERS
An overview of how international guidelines and expert working groups are updating their recommendations to include the use of fluid and imaging biomarkers for the diagnosis of mild cognitive impairment and Alzheimer’s disease.
Login Required
THE CLINICAL IMPACT OF BIOMARKERS
THE CLINICAL IMPACT OF BIOMARKERS
Prof Henry Brodaty, Scientia Professor at UNSW, and A/Prof Rebekah Ahmed, Director of the Memory and Cognition Clinic at Royal Prince Alfred Hospital, discuss recent advances in the identification of Alzheimer’s disease biomarkers, and what this may mean for future diagnosis.
Login Required
THE BRAIN BANK OF THE FUTURE
THE BRAIN BANK OF THE FUTURE
A/Prof Greg Sutherland, Deputy Director of the NSW Tissue Resource Centre, explains how advances in molecular technology have changed brain banking, and provide potential to better understand the neuropathology underlying Alzheimer’s disease.
Login Required
BRAIN BANKS AND ALZHEIMER'S DISEASE
BRAIN BANKS AND ALZHEIMER'S DISEASE
A/Prof Greg Sutherland, Deputy Director of the NSW Tissue Resource Centre, explains how brain banks can further our understanding of the early changes associated with Alzheimer’s disease and why brain banks will be important to future research.
Login Required
ARTIFICIAL INTELLIGENCE (AI) IN EARLY ALZHEIMER’S DIAGNOSIS
ARTIFICIAL INTELLIGENCE (AI) IN EARLY ALZHEIMER’S DIAGNOSIS
Dr Olivier Salvado, Lead AI CSIRO Missions and Honorary Professor, University of Queensland, explores innovations in AI which are helping researchers detect signs of Alzheimer’s disease earlier and more easily, and tells us what this might mean for future diagnosis.
Login Required